Stocks making the biggest moves premarket: Kohl's, Casey's General Stores, Vertex Pharmaceuticals and more

Kohl's Q4 revenue missed at $4.97B vs. $5.03B consensus while EPS beat at $1.07 vs. $0.85, sending shares down ~9%. Casey's Q3 revenue missed at $3.92B vs. $4.04B (shares down ~2.6%) despite an earnings beat. Vail reported EPS $5.87 and revenue $1.08B vs. $6.10 and $1.11B expected, lowered guidance due to poor Rockies weather (shares down ~1.1%); HPE beat adj. EPS $0.65 vs. $0.59 with revenue $9.30B slightly below $9.33B (shares up ~1%). TSMC sales rose ~30% year-over-year in the first two months (shares up ~1% premarket); Vertex said a drug met late-stage trial goals for IgA nephropathy, lifting shares >6%.

Analysis

The quarter shows an earnings divergence pattern: operating leverage and cost control are propping EPS while top-line demand is soft in discretionary retail and select services. That combination raises the probability of inventory correction and order pull-ins/push-outs across apparel supply chains over the next 2–6 quarters, which will compress cotton/apparel freight volumes and create winners among off-price players who can buy markdown inventory.

Leisure names are exposing an idiosyncratic-weather tail: shorter windows of good ski conditions amplify quarter-to-quarter volatility in cash flow and push more economic value into multi-year pass products and season-ticket prepayments. Equipment and resort services vendors (lift manufacturers, snowmaking, regional travel agencies) now face lumpy demand with higher probability of revenue rephasing rather than structural decline.

On the tech side the signal from semiconductors and systems is early-cycle normalization: wafer-level demand improvement should cascade to capex recovery for equipment and materials over 3–12 months, while systems vendors that beat EPS on cost control (but miss revenue) are likely converting cash flow into buybacks and margin cushions rather than organic growth. That makes short-term earnings resilience fragile if cloud/AI capex slows a quarter sooner than consensus.

Vertex’s clinical readout is a classic binary re-pricing event: successful late-stage data materially increases addressable market assumptions but creates a new set of execution risks — pricing pressure, label breadth, and manufacturing scale-up — that will determine whether the move is a durable re-rate or a near-term euphoric gap. Expect meaningful stock reaction windows at regulatory filing, PDUFA, and initial launch uptake over 6–24 months.

Key Decisions for Investors

• Short KSS / Long TJX pair (equal dollar notional). Entry: within 5 trading days on post-earnings weakness. Horizon: 3–6 months. R/R: target 15–25% relative outperformance for TJX vs KSS; stop if KSS recovers 12% absolute or TJX underperforms by 8%. Rationale: secular share shift to off-price and inventory destocking at mall-based chains.
• Short CASY (outright) or buy 3–6 month puts; hedge by going long WMT or KR (grocery exposure) 50% notional. Entry: next 10 days. Horizon: 1–3 months. R/R: expect 8–12% downside in CASY if same-store trends continue; key risk is a fuel-price driven outsized comp which would reverse trade quickly.
• Buy VRTX 6–12 month call spread (long-dated defined risk) sized to 2–4% portfolio. Entry: on any 5–10% pullback after the initial run-up. Horizon: 6–18 months. R/R: asymmetric upside (~25–50%) if launch/labeling goes broadly; primary risks are pricing/regulatory pushback and slower uptake.
• Accumulate HPE on weakness: buy 3–6 month ATM calls or buy stock and sell 3-month covered calls to finance basis. Entry: after any intra-day softening around the revenue commentary. Horizon: 3–9 months. R/R: modest upside (10–30%) from margin deleverage turning to buyback/AI spend tail; risk is an enterprise IT spend pullback that reverts EPS tailwind.